Daiwa Securities Group Inc. Travere Therapeutics, Inc. Transaction History
Daiwa Securities Group Inc.
- $21.6 Billion
- Q3 2024
A detailed history of Daiwa Securities Group Inc. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 258 shares of TVTX stock, worth $4,765. This represents 0.0% of its overall portfolio holdings.
Number of Shares
258
Previous 258
-0.0%
Holding current value
$4,765
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TVTX
# of Institutions
190Shares Held
84.7MCall Options Held
681KPut Options Held
346K-
Armistice Capital, LLC New York, NY7.65MShares$141 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$141 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$127 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$86.5 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$80.2 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.19B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...